Committee for Advanced Therapies (CAT)

Agenda for the meeting on 19-20 March 2015

Chair: Paula Salmikangas - Vice-chair: Martina Schüßler-Lenz

19 March 2015, 09:00 – 18:30, room 03-E
20 March 2015, 09:00 – 15:00, room 03-E

Health and safety information

In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
Table of contents

1. Introduction 5

1.1. Welcome and declarations of interest of members, alternates and experts .......................................................... 5
1.2. Adoption of agenda ................................................................................................................................................ 5
1.3. Adoption of the minutes ................................................................................................................................... 5
1.4. Technical information .......................................................................................................................................... 5

2. Evaluation of ATMPs 5

2.1. Opinions ............................................................................................................................................................ 5
2.2. Oral Explanations .............................................................................................................................................. 5
2.3. D180 List of Outstanding Issues (LoOIs) .......................................................................................................... 5
2.3.1. Characterized viable haploidentical Herpes Simplex Virus Thymidine Kinase (HSV-Tk) and Human Low Affinity Nerve Growth Factor Receptor (ΔLNGFR) transfected donor lymphocytes; Orphan; EMA/H/C/002801 ................................................................. 5
2.4. D120 List of Questions (LoQs) ......................................................................................................................... 5
2.5. Day 80 Assessment Report ............................................................................................................................... 5
2.6. Re-Examination Procedure (new applications) under Article 9(2) of Regulation No. 726/2004 .................................................................................................................................................. 6
2.7. Withdrawal of Initial Full Application ............................................................................................................ 6
2.8. Ongoing Initial Full Application ....................................................................................................................... 6
2.8.1. Allogeneic human heterologous liver cells; Orphan; EMA/H/C/003750 ......................................................... 6
2.9. New Applications .............................................................................................................................................. 6
2.9.1. autologous CD34+ cells transduced with retroviral vector containing the adenosine deaminase gen; Orphan; EMA/H/C/003854 ............................................................................................................................................ 6
2.10. GMP and GCP Inspections Requests ............................................................................................................ 6
2.11. Type II Variations .......................................................................................................................................... 6
2.12. Other Post-Authorisation Activities ............................................................................................................. 7
2.12.1. Glybera – alipogene tiparvovec; Orphan; EMA/H/C/002145/S/0039 ................................................................. 7

3. Certification of ATMPs 7

3.1. New Applications ............................................................................................................................................. 7
3.2. Day 60 Evaluation Reports ............................................................................................................................... 7
3.3. Opinion ........................................................................................................................................................... 7

4. Scientific Recommendation on Classification of ATMPs 7

4.1. New Requests – Appointment of CAT Co-ordinators .................................................................................... 7
4.1.1. Cell-based product made of a plasmacytoid dendritic cell line loaded with peptides from tumour antigens and irradiated .............................................................................................................. 7
4.1.2. Autologous chondrocyte transplantation system ............................................................................................ 8
4.1.3. autologous human peripheral blood Vδ1+ T lymphocytes activated in vitro by cytokine and monoclonal antibody treatment ....................................................................................................................... 8
4.2. Day 30 Co-ordinators’ First Reports ................................................................. 8
4.2.1. autologous mononuclear cells derived from human cord blood ...................... 8
4.2.2. suspension of allogeneic human adult stern cells, isolated from skeletal muscle ........ 9
4.2.3. allogeneic ex-vivo expanded placental adherent stromal cells ........................................ 9
4.2.4. allogeneic somatic cells therapy medicinal product derived from the isolation and ex vivo expansion of human Umbilical Tissue-Derived Cells ........................................... 9
4.2.5. autologous dendritic cells loaded with autologous irradiated tumour stem cells suspended in a cryopreservation medium ......................................................... 9
4.3. Finalisation of Procedure .................................................................................. 9
4.3.1. adult human bone-marrow derived, ex vivo expanded, pooled allogeneic mesenchymal stromal cells ........................................................................................................ 9
4.4. Follow-up and Guidance .................................................................................. 10
4.4.1. Reflection Paper on Classification of ATMPs .................................................... 10

5. Scientific Advice .................................................................................................. 10
5.1. New SAs – Appointment of CAT Rapporteur .................................................. 10
5.2. CAT Rapporteurs’ Reports ............................................................................. 10
5.3. List of Issues ..................................................................................................... 10
5.4. Finalisation of SA procedures ........................................................................... 10

6. Pre-Authorisation Activities .............................................................................. 10
6.1. Paediatric Investigation Plan (PIP) ................................................................. 10
6.2. ITF Briefing Meetings in the field of ATMPs .................................................. 10

7. Organisational, regulatory and methodological matters .................................. 10
7.1. Mandate and organisation of the CAT ............................................................ 10
7.1.1. Product Information process for initial MA .................................................. 10
7.1.2. Strategic Review & Learning meeting ........................................................... 11
7.1.3. Harmonisation of committees’ agenda and minutes ......................................... 11
7.1.4. CAT membership ......................................................................................... 11
7.1.5. MMD. Postponed to April ............................................................................ 11
7.2. Coordination with EMA Scientific Committees ............................................ 12
7.2.1. Committee for Medicinal Products for Human Use (CHMP) ......................... 12
7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ...... 12
7.3.1. Guideline on investigational ATMPs in clinical trials .................................... 12
7.3.2. Framework of interaction with patients and consumers and their organisations ... 12
7.3.3. GMP requirements for investigational ATMPs ............................................. 12
7.4. Cooperation within the EU regulatory network ............................................. 12
7.4.1. Meeting with National Competent Authorities for tissues and cells ................ 12
7.4.2. EU Network Training Centre ....................................................................... 13
7.5. Cooperation with International Regulators ................................................... 13
7.6. Contacts of the CAT with external parties and interaction with Interested Parties

7.7. CAT work plan

7.7.1. Work plan 2015-2016

7.8. Planning and reporting

7.9. Others


8. Any other business

Explanatory notes

Evaluation of ATMPs (section 2)

Certification of ATMPs (section 3)

Scientific Recommendation on Classification of ATMPs (Section 4)

Scientific Advice (section 5)

Pre-Authorisation (section 6)

Organisational, regulatory and methodological matters (section 7)

Any other business (section 8)
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 19-20 March 2015. See March 2015 CAT minutes (to be published post April 2015 CAT meeting).

1.2. **Adoption of agenda**

CAT agenda for 19-20 March 2015

1.3. **Adoption of the minutes**

CAT minutes for 19-20 February 2015

1.4. **Technical information**

2. **Evaluation of ATMPs**

2.1. **Opinions**

None

2.2. **Oral Explanations**

2.3. **D180 List of Outstanding Issues (LoOIs)**

2.3.1. Characterized viable haploidentical Herpes Simplex Virus Thymidine Kinase (HSV-Tk) and Human Low Affinity Nerve Growth Factor Receptor (ΔLNGFR) transfected donor lymphocytes; Orphan; EMA/H/C/002801

MolMed SpA;

**Action:** for adoption

Documents tabled:
Overview of comments by the Environmental CA ON GMO aspects
LoOIs
BWP report

2.4. **D120 List of Questions (LoQs)**

None

2.5. **Day 80 Assessment Report**

None
2.6. **Re-Examination Procedure (new applications) under Article 9(2) of Regulation No. 726/2004**

None

2.7. **Withdrawal of Initial Full Application**

None

2.8. **Ongoing Initial Full Application**

2.8.1. **Allogeneic human heterologous liver cells; Orphan; EMA/H/C/003750**

Cytonet GmbH & Co. KG.;

**Action:** for discussion

Documents tabled:
Letter received from applicant dated 12th March 2015 requesting clock-stop of the Oral Explanation to the CAT April meeting.
BWP report

Notes:
Oral report by the Rapporteurs on the outcome of the assessment of the LoOIs and questions to be addressed at the OE in April.
CAT agreed via a written procedure

2.9. **New Applications**

2.9.1. **autologous CD34+ cells transduced with retroviral vector containing the adenosine deaminase gen; Orphan; EMA/H/C/003854**

GlaxoSmithKline Trading Services- UK;

**Action:** for discussion

Document tabled:
Applicant’s submission of 13th March requesting an accelerated assessment procedure.

Notes:
Intended submission date: 05.05.15.

2.10. **GMP and GCP Inspections Requests**

None

2.11. **Type II Variations**

None
2.12. **Other Post-Approval Activities**

2.12.1. **Glybera – alipogene tiparvovec; Orphan; EMA/H/C/002145/S/0039**

UniQure Biopharma B.V.;
Rapporteur: E. French; CHMP Coordinators: G. Markey

**Action**: for information

Document tabled:
CM study: FDA /IND and CM study protocol and potential impact on current approved protocol

3. **Certification of ATMPs**

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. **New Applications**

None

3.2. **Day 60 Evaluation Reports**

None

3.3. **Opinion**

None

4. **Scientific Recommendation on Classification of ATMPs**

4.1. **New Requests – Appointment of CAT Co-ordinators**

4.1.1. **Cell-based product made of a plasmacytoid dendritic cell line loaded with peptides from tumour antigens and irradiated**

intended for the treatment of metastatic stages of cancer

ITF Coordinator:

**Action**: for adoption

Document tabled:
Request received on 26th February 2015

Notes:
Appointment of CAT Co-ordinator
Timetable

Procedure timetable:
4.1.2. **Autologous chondrocyte transplantation system**

intended for the treatment of articular cartilage defect of the knee

ITF Coordinator:

**Action**: for adoption  
Document tabled:  
Request received on 27th February 2015  
Notes:  
Appointment of CAT Co-ordinator  
Timetable  
Procedure timetable

4.1.3. **Autologous human peripheral blood Vδ1+ T lymphocytes activated in vitro by cytokine and monoclonal antibody treatment**

intended for the treatment of Chronic Lymphocytic Leukaemia, Acute Lymphoblastic Leukaemia.

ITF Coordinator:

**Action**: for adoption  
Document tabled:  
Request received on 27th February 2015  
Notes:  
Appointment of CAT Co-ordinator  
Timetable  
Procedure timetable

See also 5.2.3.

4.2. **Day 30 Co-ordinators’ First Reports**

4.2.1. **Autologous mononuclear cells derived from human cord blood**

intended for the treatment of paediatric brain damage, hypoxic-ischaemic encephalopathy, and cerebral palsy

CAT Co-ordinator: ; ITF Coordinator:

**Action**: for adoption  
Document tabled:  
Co-ordinator’s draft report
### 4.2.2.  
**Suspension of allogeneic human adult stern cells, isolated from skeletal muscle**

Intended for the treatment of Duchenne Muscular

**CAT Co-ordinator:**  ;  **EMA resources:**

**Action:** for adoption

**Document tabled:**

**Co-ordinator’s draft report**

---

### 4.2.3.  
**Allogeneic ex-vivo expanded placental adherent stromal cells**

Intended for the treatment of Peripheral Arterial Occlusive Disease (PAOD)

**CAT Co-ordinator:**  ;  **ITF Coordinator:**

**Action:** for adoption

**Documents tabled**

**Co-ordinator’s draft report**

---

### 4.2.4.  
**Allogeneic somatic cells therapy medicinal product derived from the isolation and ex vivo expansion of human Umbilical Tissue-Derived Cells**

Intended improvement of visual acuity in patients with vision loss from geographic atrophy secondary to age-related macular degeneration

**CAT Co-ordinator:**  ;  **ITF Coordinator:**

**Action:** for adoption

**Document tabled:**

**Co-ordinator’s draft report**

---

### 4.2.5.  
**Autologous dendritic cells loaded with autologous irradiated tumour stem cells suspended in a cryopreservation medium**

Intended for the treatment of melanoma.

**CAT Co-ordinator:**  ;  **ITF Coordinator:**

**Action:** for adoption

**Document tabled:**

**Co-ordinator’s draft report**

---

### 4.3.  
**Finalisation of Procedure**

#### 4.3.1.  
**Adult human bone-marrow derived, ex vivo expanded, pooled allogeneic mesenchymal stromal cells**

Intended for the treatment of thromboangiitis obliterans (Buerger’s disease)

**CAT Co-ordinator:**  ;  **ITF Coordinator:**

**Action:** for information

**Document tabled:**

**Co-ordinator’s adopted report**
Note:
The commission made some observations that did not require an amendment to the report

4.4. Follow-up and Guidance

4.4.1. Reflection Paper on Classification of ATMPs

DG on substantial manipulation:
DG on non-homologous use:
EMA resources:

Action: for discussion
Oral updates of DGs

Notes:
DG members to meet on Thursday 19th March in room 03-L from 18:30-19:30hrs

5. Scientific Advice

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New SAs – Appointment of CAT Rapporteur

5.2. CAT Rapporteurs’ Reports

5.3. List of Issues

5.4. Finalisation of SA procedures

6. Pre-Authorisation Activities

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric Investigation Plan (PIP)

None

6.2. ITF Briefing Meetings in the field of ATMPs

None

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. Product Information process for initial MA

The process has been revised for the review of the Product Information for initial Marketing Authorisation in the centralised procedure
EMA resources: - Labelling Review and Standards Office

**Action:** for information

### 7.1.2. Strategic Review & Learning meeting

CAT-CHMP joint Strategic Review & Learning meeting (formerly known Informal meeting) to be held in Ljubljana (Slovenia) on 27th-28th May 2015 under the auspices of the Latvian Presidency of the Council of the European Union

CAT resources: Metoda Lipnik-Stangelj, Una Riekstina

**Action:** for discussion

Documents tabled:
Draft agenda

Notes:
Information on reimbursement of members/alternates nominated by the European Commission (Civil Societies)

### 7.1.3. Harmonisation of committees’ agenda and minutes

Implementation of the new agenda template and on the development of Service Level Agreements (SLAs) for the minutes.

EMA resources:

**Action:** for information

### 7.1.4. CAT membership

Italy: Paolo Gasparini’s membership expired on 1st February 2015

Poland: Dariusz Śladowski’s membership expired on 28th February 2015

France: Sophia Lucas terminated her alternate membership on 9th March 2015

EMA resources:

**Action:** for information

### 7.1.5. MMD. Postponed to April

Training session on MMD. Send any questions/query/issue in advanced to CATSecretariat@ema.europa.eu

CAT resources:

**Action:** for discussion

Document(s) tabled:
Questions and queries
7.2. **Coordination with EMA Scientific Committees**

7.2.1. **Committee for Medicinal Products for Human Use (CHMP)**

Table of Decisions for the February 2015 meeting

**Action:** for information

7.3. **Coordination with EMA Working Parties/Working Groups/Drafting Groups**

7.3.1. **Guideline on investigational ATMPs in clinical trials**

CAT members interested to join this drafting group should inform the CAT secretariat in advance of the March meeting. A teleconference call will be organised in advance of the April CAT meeting to initiate the work of the DG.

CAT resources: Paula Salmikangas; EMA resources:

Nominations received:

**Action:** for adoption

Documents tabled:
Letter from Commission dated 26th January 2015

Notes:
Appointment of drafting group members

7.3.2. **Framework of interaction with patients and consumers and their organisations**

The framework has been revised.

EMA resources: – Patients and Healthcare Professionals Dept.

**Action:** for information

7.3.3. **GMP requirements for investigational ATMPs**

CAT drafting group members: **Action:** for discussion

Notes:
Feedback on the outcome of the DG meeting of 18.03.15.

7.4. **Cooperation within the EU regulatory network**

7.4.1. **Meeting with National Competent Authorities for tissues and cells**

Joint meeting between CAT and NCAs responsible for tissues and cells / medicines to take place on 23rd April 2015 at the European Commission

CAT resources: Paula Salmikangas

**Action:** for discussion

Document tabled:
Agenda

Notes:
Appointment of CAT members to attend the meeting

7.4.2. **EU Network Training Centre**

The EU Network Training Centre is a joint initiative of the EMA and HMA. The EU NTC has recently launched its new interim platform, a website containing the first catalogue of trainings accessible to the entire Network: http://euntc.eudra.org/index.html

EMA resources: – EU Network Training Centre

**Action:** for information

7.5. **Cooperation with International Regulators**

None

7.6. **Contacts of the CAT with external parties and interaction with Interested Parties**

None

7.7. **CAT work plan**

7.7.1. **Work plan 2015-2016**

Objective 1: organise a webinar for the NCAs on ATMP classification. The aim is to explain on basis of practical examples the principles described in the Reflection Paper on ATMP classification. It is proposed to organise a one-hour webinar in the margins of the June CAT meeting.

Objective 2: Analysis of EudraCT for ATMP trials between 2011 and 2014.

EMA resources:

**Action:** for discussion

7.8. **Planning and reporting**

None

7.9. **Others**


EMA resources:

**Action:** for information

Document tabled:
Guide
8. **Any other business**

None

Date of next CAT meeting:
Thursday 16th – Friday 17th April 2015
Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

The notes below give a brief explanation of relevant items and should be read in conjunction with the agenda.

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a Day 120 list of questions (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (Ongoing evaluation procedures). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.
Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

**Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)**

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

**Withdrawal of applications (section 2.7.)**

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

**New applications (section 2.9.)**

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

**GMP and GCP Inspections Issues (section 2.10.)**

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

**Post-authorisation activities (section 2.12.)**

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

**Certification of ATMPs (section 3)**

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

**Scientific Recommendation on Classification of ATMPs (Section 4)**

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).
Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/